Managing Amyloid-Related Imaging Abnormalities in Alzheimer Disease

Managing Amyloid-Related Imaging Abnormalities in Alzheimer Disease

Panelists discuss how amyloid-related imaging abnormalities, including brain swelling and bleeding, can occur in patients receiving monoclonal antibody therapies for Alzheimer disease, necessitating careful monitoring through MRI scans, dose adjustments, and supportive care to manage risks—particularly in individuals with genetic risk factors—while ongoing research seeks safer, more effective treatments and improved detection strategies.

NKGen Biotech Administers First Dose of Troculeucel to Alzheimers Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy

July 10, 2025 16:30 ET  | Source: NKGen Biotech, Inc. SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first […] The post NKGen Biotech Administers First Dose of Troculeucel t…